- Home
- STN vs RPRX Comparison
STN vs RPRX Comparison
Compare STN & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STN
- RPRX
- Stock Information
- Founded
- STN 1954
- RPRX 1996
- Country
- STN Canada
- RPRX United States
- Employees
- STN N/A
- RPRX N/A
- Industry
- STN Military/Government/Technical
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- STN Consumer Discretionary
- RPRX Health Care
- Exchange
- STN Nasdaq
- RPRX Nasdaq
- Market Cap
- STN 12.0B
- RPRX 13.9B
- IPO Year
- STN N/A
- RPRX 2020
- Fundamental
- Price
- STN $105.32
- RPRX $34.86
- Analyst Decision
- STN
- RPRX Strong Buy
- Analyst Count
- STN 0
- RPRX 3
- Target Price
- STN N/A
- RPRX $47.33
- AVG Volume (30 Days)
- STN 159.6K
- RPRX 4.8M
- Earning Date
- STN 08-06-2025
- RPRX 08-07-2025
- Dividend Yield
- STN 0.59%
- RPRX 2.53%
- EPS Growth
- STN 14.85
- RPRX 37.60
- EPS
- STN 2.34
- RPRX 2.45
- Revenue
- STN $4,208,787,002.00
- RPRX $2,263,845,000.00
- Revenue This Year
- STN $11.87
- RPRX $29.35
- Revenue Next Year
- STN $7.82
- RPRX $7.58
- P/E Ratio
- STN $44.95
- RPRX $14.18
- Revenue Growth
- STN 16.16
- RPRX 1.13
- 52 Week Low
- STN $73.18
- RPRX $24.05
- 52 Week High
- STN $108.34
- RPRX $35.38
- Technical
- Relative Strength Index (RSI)
- STN 59.92
- RPRX 61.71
- Support Level
- STN $106.36
- RPRX $33.37
- Resistance Level
- STN $108.18
- RPRX $35.38
- Average True Range (ATR)
- STN 1.52
- RPRX 0.60
- MACD
- STN -0.56
- RPRX 0.12
- Stochastic Oscillator
- STN 47.93
- RPRX 80.95
About STN Stantec Inc
Stantec Inc is a sustainable engineering, architecture, and environmental consulting company. It offers services through the following business operating units; Environmental Services, Infrastructure, Water, Buildings, and Energy & Resources. Maximum revenue is derived from its Infrastructure business unit, which is engaged in evaluating, planning, and designing infrastructure solutions for transportation, community development, and urban spaces. The company's reportable segments are the United States, which derives maximum revenue, Canada, and Global. These segments provide consulting in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics services in the area of infrastructure and facilities.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.